米氮平治疗抑郁症的临床研究

目的评价米氮平治疗抑郁症的疗效及安全性。方法将符合中国精神障碍分类与诊断标准（第3版）．抑郁症诊断标准60例，随机分为两组。米氨平组（30例），马普替林组（30例）治疗6周采用汉密尔顿郁量表（HAMD）评定疗效。采用副反应量表（TESS）评定不良反应。结果米氨平显效率为83．3％。马普替林组显效率76．7％，两组差异无显著性。HAMD减分率，米氨平组明显多于马普替林组，米氮平组不良反应较少而轻微。结论米氮平是一种安全高效耐受好、副反应小、应用范围广的抗抑郁药。可作为一线抗抑郁药物使用。

Clinical Study of Mirtazapine in the Treatmemt of Depressive Disorder

Objective To evaluate the effiacy and safety of mirtazapine in the trentment of deprvession.Methods 60 Patients with deperssion met with chinese classification and Diagnosisitic criteria of mental Disarders third edition criteria were randomly assigned to mirtazapine group and maprotiline group for six weeks treatment.Hanilton depressive scal(HAMD) and theatment emergent symptom scale(TESS) were used to a ssess the clinical efficacy and side effects.Results The significant improvementd rate of mirtazapine was 83.3% and that of maprotiline was 76.7%.These was no Significant difference between the two groups The score of HAMD was reducad more in mirtazapine group than in maprotilin group.The adverse Reactions of mirtazapinewere lower and 1ighter then that of maprotiline.Conclusion Mirtaznpine is a safety and ettective antidepressent drug with good toleration,which can be used clinicalcy as the first choice.